Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is ...

The FDA has outlined numerous concerns about the sale and use of unapproved GLP-1 drugs for weight loss.  “FDA is aware that ...

Hims is breaching the US patent on semaglutide, the active ingredient in Novo’s blockbuster obesity treatments, Novo argued ...

Hims & Hers Health shares plunged Monday after the telehealth company said it would stop selling its compounded weight-loss ...

The FDA announced Friday that it intends to restrict the active pharmaceutical ingredients of glucagon-like peptide-1 (GLP-1) receptor agonists used in unapproved compounded drugs that are being ...

By Leah Douglas and Siddhi Mahatole Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it would take ...

Novo Nordisk is suing US telehealth company Hims & Hers to stop it selling “knock-off” versions of its weight-loss drugs, as Hims’ shares sank more than 20 per cent after regulators announced an ...

Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with ...

By Anusha Shah and Amina Niasse Feb 7 (Reuters) - Online telehealth company Hims & Hers on Saturday reversed course on its ...

Novo's lawsuit comes less than one week after Hims & Hers announced plans to sell a compounded version of Novo's weight-loss ...

Hims & Hers (NYSE:HIMS) shares are plunging 16% in after-hours trading following coordinated moves by two federal agencies ...

Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in ...